COMPLliancE and qualiTy of lifE in Asthma (COMPLETE)
Multicenter, Open-label, Non Interventional, Prospective, Observational Clinical Trial to Assess the Compliance and Quality of Life in Greek Asthmatic Patients
調査の概要
状態
条件
詳細な説明
Dry powder devices, available since 1970, have been developed to make inhalation simpler than pMDIs and relieve the need for co-ordination of spraying and inhalation, which is particularly important for patient groups such as the elderly and children. In addition, dry powder devices do not contain propellant gases potentially hostile to the environment as they are activated by inhalation of the patient and do not cause cold sensation upon inhalation.
Today, the combination of inhaled corticosteroid (ICS) and long-acting β2-inducer with an inhaler is the basic treatment for asthma6.
The addition of long-acting β2-inducer (LABA) to a daily inhaled corticosteroid regimen1:
- Improves the symptoms,
- Reduces nightly asthma symptoms,
- Improves pulmonary function,
- Reduces the use of β2-agonists for rapid action,
- Reduces the number of seizures,
- Does not increase the risk of hospitalizations due to asthma,
- Achieves clinical asthma control in more patients, faster and with less ICS than would be required if ICS were administered alone.
The greater effectiveness of combination therapy has led to the development of stable combination inhalers that both glucocorticosteroids and LABA (eg, fluticasone-salmeterol, budesonide-formoterol stable compounds) are concomitantly conveyed.
Stable combinations are more user-friendly for patients, potentially increasing compliance, and ensure that LABA is always accompanied by glucocorticosteroid1. Of the combinations available, the budesonide-formoterol combination can be used both as maintenance therapy and symptom relief due to the rapid onset of formoterol compared to salmeterol. Both components of the budesonide-formoterol combination when administered are helpful in enhancing protection from severe seizures in patients receiving combination therapy for maintenance and improve the control of asthma at relatively low ICS doses.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
-
Athens、ギリシャ
- Sotiria Pulmonary Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Male or female asthma patients over 18 years of age
- Compliance with treatment
- Compliance with study procedures
- Signed informed consent form
Patients not satisfactorily controlled with inhaled corticosteroids and the use of inhaled short-acting β2-primers or patients already adequately controlled with both inhaled corticosteroids and long-acting β2-stimulants:
- Patients receiving ICS inhaled and SABA invoked
- Patients receiving inhaled ICS and LABA with separate devices each
- Patients receiving periodic and not continuously stable combination of ICS and LABA but not being treated for at least 1 month
- Patients who did not receive any treatment and the doctor decides to immediately start the fixed combination of ICS and LABA
Exclusion Criteria:
- Male or female asthma patients under 18 years of age
- Unsigned patient consent
- Non-compliance with treatment
- Non-compliance in study procedures
- COPD patients (at any stage)
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Quality of Life
時間枠:6 months
|
Change in mini AQLQ scale
|
6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Compliance
時間枠:6 months
|
Change in MMAS-8 scale
|
6 months
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
生活の質の臨床試験
-
Hôpital Léon Bérard完了
-
Queens College, The City University of New York募集American Journal of Public Healthに投稿された論文の出版アメリカ
-
Swansea University完了A Bite of ACT' (BOA) Acceptance and Commitment Therapy オンライン心理教育コース | 待機リスト コントロールイギリス
-
Scripps Translational Science Institute完了